ContraFect to Present at 2017 World Antimicrobial Resistance Congress
September 11, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 11, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Announces Second Quarter 2017 Financial Results
August 09, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - August 09, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present New Clinical and Microbiological Data on CF-301 at ASM Microbe 2017
June 01, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - June 01, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Chairman Steven C. Gilman Returns from Temporary Medical Leave
May 30, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - May 30, 2017) - ContraFect Corporation (NASDAQ: CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics...
ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia
May 25, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - May 25, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Announces First Quarter 2017 Financial Results
May 08, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - May 08, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
April 19, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - April 19, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program
March 30, 2017 11:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - March 30, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Chairman and CEO Steven C. Gilman Takes Temporary Medical Leave
March 13, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - March 13, 2017) - ContraFect Corporation (NASDAQ: CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
Lisa Ricciardi to Join Board of Directors
February 15, 2017 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - February 15, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...